Novo Nordisk's STEP UP trial shows that the higher 7.2 mg dose of Wegovy (semaglutide) enables early responders to lose an average of 27.7% body weight after 72 weeks, significantly more than the 2.4 mg dose or placebo. Most weight loss came from fat reduction (84%), with muscle mass largely preserved and muscle function improved. These findings highlight Wegovy's effectiveness and safety in treating obesity, offering hope for better long-term weight management. Novo Nordisk presented these results at the 2026 European Congress on Obesity and plans further publication.
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...
Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) demonstrated significant weight loss and mobility improvements in adults with obesity in the phase 3 OASIS 4 trial. Nearly 29% of early responders lost an average of 21.6% body weight by week 64, wh...
Novo Nordisk disclosed that two closely associated persons of its CFO, Karsten Munk Knudsen, received 50 shares each as gifts on May 7, 2026. The shares were valued around DKK 294 per share and the transactions occurred outside a trading venue. This ...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
Novo Nordisk's Wegovy® (semaglutide) demonstrated significant weight loss averaging 22.6% in premenopausal women and consistent results across all menopause stages, with major reductions in waist circumference. The drug also lowered risks of migraine...
